BMS-753426

sel. CCR2 chemokine receptor antagonist

oral efficacy (25 mpk BID) in inflamm. models

from PK opt. of prior candidate

ACS Med. Chem. Lett., May 25, 2021

Bristol Myers Squibb, Princeton, NJ

The BMS CCR2 inhibitor, BMS-753426, is a potent, oral follow-up molecule to prior clinical candidate, BMS-741672. A small change from a methyl and isopropyl-substituted tertiary amine to a t-butyl secondary amine…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks